Abdurrahmaan Ali Suei Elbuzidi: What is the Optimal Anticoagulation Monitoring Target in ECMO?
Abdurrahmaan Ali Suei Elbuzidi, ECMO and Critical Care Consultant at Hamad Medical Corporation, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Journal of Cardiothoracic and Vascular Anesthesia, adding:
“Excited to share that our latest systematic review and meta-analysis has been published:
‘Clinical Outcomes of Different Heparin Anticoagulation Monitoring Targets in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis.’
This work explores an important and ongoing challenge in ECMO care:
What is the optimal anticoagulation monitoring target?
Despite widespread use of unfractionated heparin in ECMO, significant variability remains in monitoring strategies (ACT, aPTT, anti-Xa, and others), with potential implications for bleeding, thrombosis, and overall patient outcomes.
Our review aimed to synthesize the available evidence and evaluate how different monitoring targets may influence clinical outcomes.
Proud to have collaborated with an outstanding multidisciplinary team of colleagues on this project.Special thanks to all co-authors for their dedication and contributions.
Looking forward to continued research that helps refine anticoagulation strategies and improve outcomes for ECMO patients.”
Title: Clinical Outcomes of Different Heparin Anticoagulation Monitoring Targets in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-analysis
Authors: Alaa Rahhal, Ans Alamami, Rabee Tawel, Ahmed Shebani, Hassan Fahed El Daezli, Abdurrahmaan Elbuzidi, Nadir Kharma, Amr Omar, Ahmed Labib Shehatta
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 9, 2026, 10:02Understanding Factor X Deficiency – ICHCC
-
Jun 9, 2026, 09:49Lee Severin: Why Patients Love Platelet-Rich Plasma
-
Jun 9, 2026, 09:42Lorena Gerlach: Blood Transportation Duty on this Muggy Spring Day
-
Jun 9, 2026, 08:54Shujha Abbas: Understanding the Real Cost of Gene Therapie
-
Jun 9, 2026, 04:47Akshat Jain: Marstacimab Gets FDA Expension for Children with Hemophilia B
-
Jun 9, 2026, 03:30Fayad Al-Haimus: High-Risk Emergencies and Lifelong Learning at CAEP 2026
-
Jun 9, 2026, 03:14Rucha Patil: A Collaborative Initiative to Transform Rare Blood Disorder Care in Rajasthan
-
Jun 9, 2026, 02:28Andreas Calatzis: Chasing Biologically Inactive Heparin?
-
Jun 9, 2026, 02:16Javier Lagos Servellon: Reflections on Completing the University of Bern’s Stroke Medicine Program